Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Clinical Trials IT and Development Lead
Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med
-
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Journal article
Munro APS. et al, (2022), Lancet Infect Dis
-
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2022), J Infect
-
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Journal article
Lazarus R. et al, (2021), Lancet, 398, 2277 - 2287
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2021), Lancet
-
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Journal article
Munro APS. et al, (2021), Lancet
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
-
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), Sci Transl Med, 13
-
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article
Feng S. et al, (2021), Nat Med, 27, 2032 - 2040
-
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Journal article
Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568
-
Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Journal article
Theiss-Nyland K. et al, (2021), Clin Infect Dis
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Journal article
Clemens SAC. et al, (2021), Nat Commun, 12
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Journal article
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
-
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Journal article
Qadri F. et al, (2021), Lancet, 398, 675 - 684
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Journal article
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
-
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), medRxiv
-
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article
Liu X. et al, (2021), SSRN Electronic Journal
-
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Journal article
Flaxman A. et al, (2021), SSRN Electronic Journal
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nat Med, 27
-
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Ewer KJ. et al, (2021), Nat Med, 27
-
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
-
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Journal article
Madhi SA. et al, (2021), N Engl J Med, 384, 1885 - 1898
-
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection
Frater J. et al, (2021)
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
Successful incorporation of a genetic risk prediction research platform into routine newborn screening
Journal article
Bendor-Samuel OM. et al, (2021)